Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors

Pediatric Blood and Cancer

Volumn 58, Issue 3, 2012, Pages 441-447

  Chueh, Hee Won ^a   Sung, Ki Woong ^a   Lee, Soo Hyun ^a   Yoo, Keon Hee ^a   Koo, Hong Hoe ^a   Kim, Ju Youn ^a   Cho, Eun Joo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Autologous stem cell transplantation; Deferasirox; Fanconi syndrome; Hepatic veno occlusive disease; High dose chemotherapy; Iron chelation treatment

Indexed keywords

DEFERASIROX; FERRITIN; HEPARIN; IRON; PROSTAGLANDIN E1;

ABDOMINAL PAIN; ADOLESCENT; ANAPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BRAIN TUMOR; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FANCONI RENOTUBULAR SYNDROME; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INDUCTION CHEMOTHERAPY; IRON BLOOD LEVEL; IRON CHELATION; KIDNEY DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; MALE; NAUSEA; NEUROBLASTOMA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; VOMITING;

ACUTE KIDNEY INJURY; BENZOIC ACIDS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FANCONI SYNDROME; FEMALE; FERRITINS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; IRON CHELATING AGENTS; MALE; NEUROBLASTOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRIAZOLES;

EID: 84862908929     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23198     Document Type: Article

References (29)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-1173.
2. Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998; 16: 210-221.
3. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006; 24: 2891-2896.
4. Sung KW, Lee SH, Yoo KH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 2007; 40: 37-45.
5. Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primivitve neuroectodermal tumor. Pediatr Blood Cancer 2007; 48: 408-415.
6. Sung KW, Ahn HS, Cho B, et al. Efficacy of tandem high-dose chemotherapy and autologous tem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: The Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005). J Korean Med Sci 2010; 25: 691-697.
7. Lee SH, Yoo KH, Sung KW, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: Incidence, risk factors, and outcome. Bone Marrow Transplant 2010; 45: 1287-1293.
8. Lee JW, Kang HJ, Kim EK, et al. Effect of iron overload and iron-chelating therapy on allogenic hematopoietic SCT in children. Bone Marrow Transplant 2009; 44: 793-797.
9. Altès A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 987-989.
10. Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114: 1270-1275.
11. Giardini C, Galimberti M, Lucarelli G, et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br J Haematol 1995; 89: 868-873.
12. Unal S, Kuskonmaz B. Deferasirox use after hematopoietic stem cell transplantation in pediatric patients with β-thalassemia major: Preliminary results. Pediatr Hematol Oncol 2010; 27: 482-489.
13. Gaziev D, Giardini C, Angelucci E, et al. Intravenous chelation therapy during transplantation for thalassemia. Haematologica 1995; 80: 300-304.
14. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica 2006; 91: 1343-1351.
15. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752-759.
16. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study. Eur J Haematol 2009; 82: 458-465.
17. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: A clinical review. Clin Ther 2007; 29: 2154-2166.
18. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-1150.
19. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
20. Caoline L, Rosner F, Kozinn PJ. Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood 1969; 34: 441-451.
21. Fenaux P, Rose C. Impact of iron overload in myelodysplatic syndromes. Blood Rev 2009; 23: S15-S19.
22. Neupane GP, Kim DM. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus Transfusion 2009; 49: 1762-1769.
23. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21: 620-625.
24. Kwiatkowski JL. Oral iron chelators. Hematol Oncol Clin N Am 2010; 24: 229-248.
25. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
26. Kontoghiorghes GJ. Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007; 6: 235-239.
27. Yew ST, Talaulikar GS, Falk MC, et al. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology 2010; 5: 377.
28. Grangé S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010; 25: 2376-2378.
29. Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in beta-Thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 2010; 32: 564-567.